Advertisement LTS Expands Into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

LTS Expands Into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business

LTS LOHMANN Therapie-Systeme (LTS), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (TTS), Oral Thin Films (OTF) and Micro Array Patches (MAP), announces the signing of the acquisition of the Sorrel wearable injection device business (Sorrel), a part of Eitan Medical.

The acquisition is a crucial step in LTS’ strategy to broaden its portfolio of drug delivery platforms. Sorrel’s large volume wearable injector technologies will enable LTS to go beyond its current passive technology offerings. It opens new opportunities for LTS to support pharma partners in the field of large molecules and biologics.

Based in Netanya, Israel, Eitan Medical is a global leader in advanced infusion therapy and drug delivery solutions with reliable innovations that put patients at the centre of care, making drug delivery easier and safer than ever before. Within Eitan Medicals, Sorrel provides an innovative solution for the subcutaneous delivery of large-molecule drugs. These connected, pre-filled and pre-loaded wearable devices enable patients living with chronic and high-burden conditions to self-administer medication safely and efficiently without interrupting their daily lives.

Bas van Buijtenen, CEO of LTS, commented: “The acquisition of the Sorrel platform catapults LTS into the world of drug delivery for large molecules, and fulfils our mission to bring empowering solutions to patients that rely on cumbersome and expensive therapies requiring in-clinic administration or multiple injections. Sorrel’s solutions set a new standard for performance, quality, reliability and patient convenience in wearable injection devices. The Sorrel platform is now ready for commercial launch and will accelerate its scale-up within LTS, benefiting from LTS’s global reach and reputation. We are excited to welcome Dr Andrei Yosef and his talented team to our organisation”.

Boaz Eitan PhD, CEO and chairman of Eitan Medical, commented: “The acquisition of Sorrel, a company that evolved to be a leader in its space, comes as testament to Eitan Medical’s capabilities. This transaction will allow us to focus on our core business, Medication Delivery Solutions, and continue to innovate in the drug delivery market. At this point, I would like to thank Igal Shany for leading this transaction.”

Andrei Yosef, PhD, general manager of Sorrel, added: “The acquisition by LTS will accelerate the growth of Sorrel and benefit our multiple pharma partners. Sorrel’s platform commercial launch is planned for this year together with additional clinical trials with our pharma partners. LTS, with its reputation, strong leadership, scale, and combination product capabilities will expedite our growth. Sorrel’s patient-centric on-body drug delivery platform is improving patient comfort and adherence with a reliable easy-to-use drug delivery device for self-administration at home.”